You keep the product and the technology. We carry regulatory clearance, quality systems, local production, design adaptation, field sales and service.
A manufacturer with a proven device in its home market usually faces the same wall abroad: a regulatory pathway it has never run, a quality system it does not hold, a design that does not match local clinical habit, and no way to reach a hospital purchasing committee. Building all of that takes years and a local entity.
We already operate that infrastructure. A partner product enters it rather than reproducing it — which means the cost of market entry is shared across the lines the platform already carries instead of being paid from scratch.
No local entity is required of the partner. Commercial terms, specialty positioning and target markets are agreed line by line.
Product lines are grouped by clinical specialty so that partner brands complement rather than compete with each other inside the same channel.
A line can enter under its own brand, under a co-brand, or as a private-label product, depending on what serves the market and the partner.
A new line inherits surgeon relationships and purchasing pathways that already exist, rather than opening accounts from zero.
The hospital carries no capital cost. The console is placed on site and revenue is earned through recurring high-value disposables. This accounts for the largest share of our installed base.
The hospital purchases the console through its capital budget, with a long-term disposables supply agreement and annual service coverage.
A bridge structure with an agreed volume threshold, used while a new account ramps up.
Demonstration and loaner units enter the hospital evaluation process and convert into permanent placements.
US regulatory clearance and clinical data support entry into Israel and the Middle East through distribution partners.
Terms, specialty fit and target markets are discussed brand by brand.